Literature DB >> 2874041

Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding.

P A Hals, H Hall, S G Dahl.   

Abstract

The in vitro binding affinities of levomepromazine, chlorpromazine, fluphenazine, perphenazine and methoxypromazine and their main metabolites to dopamine D2 receptors, alpha 1- and alpha 2-adrenoceptors in rat brain, were examined using [3H]spiperone, [3H]WB 4101 and [3H]yohimbine binding. All compounds had 10-500 times lower affinities to alpha 2-adrenoceptors than to dopamine D2 receptors and alpha 1-adrenoceptors. Ring-hydroxylated and N-demethylated metabolites had relative potencies for dopamine D2 receptor and alpha 1-adrenoceptor binding ranging from 20 to 70%, compared to that of the parent drugs. The ring sulphoxides of levomepromazine, chlorpromazine and perphenazine, except dextro levomepromazine sulphoxide, were virtually inactive in all binding systems. The results indicate that the metabolites having the highest binding affinities for dopamine D2 receptor and alpha 1-adrenoceptor binding may contribute significantly to the therapeutic effect and side-effects of the drugs, and should be measured together with the parent drugs in blood level-effect studies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874041     DOI: 10.1016/0014-2999(86)90793-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.

Authors:  O V Olesen; K Linnet
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

2.  Theoretical study on the metabolic mechanisms of levmepromazine by cytochrome P450.

Authors:  Yongting Wang; Qiu Chen; Zhiyu Xue; Yan Zhang; Zeqin Chen; Ying Xue
Journal:  J Mol Model       Date:  2016-09-13       Impact factor: 1.810

3.  Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism.

Authors:  Scott D Philibin; D Matthew Walentiny; Sarah A Vunck; Adam J Prus; Herbert Y Meltzer; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2008-11-07       Impact factor: 4.530

4.  Clinical pharmacology of prochlorperazine in healthy young males.

Authors:  A O Isah; M D Rawlins; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

5.  Anti-apomorphine effects of phenothiazine drug metabolites.

Authors:  E Morel; K G Lloyd; S G Dahl
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Metabolism of levomepromazine in man.

Authors:  P A Hals; S G Dahl
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jan-Mar       Impact factor: 2.441

7.  Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.

Authors:  Ken Morita; Shuning He; Radosław P Nowak; Jinhua Wang; Mark W Zimmerman; Cong Fu; Adam D Durbin; Megan W Martel; Nicole Prutsch; Nathanael S Gray; Eric S Fischer; A Thomas Look
Journal:  Cell       Date:  2020-04-20       Impact factor: 66.850

8.  Acepromazine inhibits hERG potassium ion channels expressed in human embryonic kidney 293 cells.

Authors:  Young Shin Joo; Hong Joon Lee; Jin-Sung Choi; Ki-Wug Sung
Journal:  Korean J Physiol Pharmacol       Date:  2016-12-21       Impact factor: 2.016

9.  Molecular mechanisms underlying variations in lung function: a systems genetics analysis.

Authors:  Ma'en Obeidat; Ke Hao; Yohan Bossé; David C Nickle; Yunlong Nie; Dirkje S Postma; Michel Laviolette; Andrew J Sandford; Denise D Daley; James C Hogg; W Mark Elliott; Nick Fishbane; Wim Timens; Pirro G Hysi; Jaakko Kaprio; James F Wilson; Jennie Hui; Rajesh Rawal; Holger Schulz; Beate Stubbe; Caroline Hayward; Ozren Polasek; Marjo-Riitta Järvelin; Jing Hua Zhao; Deborah Jarvis; Mika Kähönen; Nora Franceschini; Kari E North; Daan W Loth; Guy G Brusselle; Albert Vernon Smith; Vilmundur Gudnason; Traci M Bartz; Jemma B Wilk; George T O'Connor; Patricia A Cassano; Wenbo Tang; Louise V Wain; María Soler Artigas; Sina A Gharib; David P Strachan; Don D Sin; Martin D Tobin; Stephanie J London; Ian P Hall; Peter D Paré
Journal:  Lancet Respir Med       Date:  2015-09-21       Impact factor: 30.700

10.  Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment.

Authors:  Pareesa Kamgar-Dayhoff; Tinatin I Brelidze
Journal:  Oncotarget       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.